News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
725,055 Results
Type
Article (41342)
Company Profile (297)
Press Release (683406)
Multimedia
Podcasts (89)
Webinars (17)
Section
Business (205613)
Career Advice (2037)
Deals (35655)
Drug Delivery (112)
Drug Development (81594)
Employer Resources (173)
FDA (16449)
Job Trends (15002)
News (347707)
Policy (32839)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2586)
Accelerated approval (34)
Adcomms (24)
Allergies (142)
Alliances (49922)
ALS (171)
Alzheimer's disease (1679)
Antibody-drug conjugate (ADC) (317)
Approvals (16719)
Artificial intelligence (519)
Autoimmune disease (160)
Automation (41)
Bankruptcy (364)
Best Places to Work (11658)
BIOSECURE Act (21)
Biosimilars (193)
Biotechnology (190)
Bladder cancer (159)
Brain cancer (57)
Breast cancer (641)
Cancer (4845)
Cardiovascular disease (402)
Career advice (1721)
Career pathing (36)
CAR-T (286)
CDC (45)
Celiac Disease (2)
Cell therapy (757)
Cervical cancer (36)
Clinical research (69739)
Collaboration (1732)
Company closure (4)
Compensation (1168)
Complete response letters (57)
COVID-19 (2729)
CRISPR (94)
C-suite (864)
Cystic fibrosis (145)
Data (6272)
Decentralized trials (2)
Denatured (30)
Depression (136)
Diabetes (503)
Diagnostics (6720)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (259)
Drug pricing (187)
Drug shortages (28)
Duchenne muscular dystrophy (233)
Earnings (90368)
Editorial (57)
Employer branding (21)
Employer resources (152)
Events (117881)
Executive appointments (988)
FDA (19592)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1491)
Gene editing (202)
Generative AI (43)
Gene therapy (602)
GLP-1 (970)
Government (4679)
Grass and pollen (6)
Guidances (384)
Healthcare (18898)
HIV (60)
Huntington's disease (46)
IgA nephropathy (83)
Immunology and inflammation (262)
Immuno-oncology (59)
Indications (115)
Infectious disease (3007)
Inflammatory bowel disease (195)
Inflation Reduction Act (16)
Influenza (119)
Intellectual property (254)
Interviews (315)
IPO (16676)
IRA (52)
Job creations (3677)
Job search strategy (1440)
JPM (57)
Kidney cancer (16)
Labor market (86)
Layoffs (557)
Leadership (32)
Legal (7987)
Liver cancer (91)
Longevity (14)
Lung cancer (653)
Lymphoma (379)
Machine learning (42)
Management (59)
Manufacturing (807)
MASH (164)
Medical device (13786)
Medtech (13840)
Mergers & acquisitions (20053)
Metabolic disorders (1275)
Multiple sclerosis (163)
NASH (16)
Neurodegenerative disease (322)
Neuropsychiatric disorders (89)
Neuroscience (2924)
Neurotech (1)
NextGen: Class of 2026 (6556)
Non-profit (4526)
Now hiring (67)
Obesity (599)
Opinion (265)
Ovarian cancer (167)
Pain (199)
Pancreatic cancer (231)
Parkinson's disease (282)
Partnered (35)
Patents (506)
Patient recruitment (497)
Peanut (56)
People (59241)
Pharmaceutical (66)
Pharmacy benefit managers (29)
Phase 1 (21758)
Phase 2 (30694)
Phase 3 (22857)
Pipeline (5392)
Policy (287)
Postmarket research (2565)
Preclinical (9237)
Press Release (64)
Prostate cancer (238)
Psychedelics (48)
Radiopharmaceuticals (282)
Rare diseases (848)
Real estate (6000)
Recruiting (70)
Regulatory (24605)
Reports (53)
Research institute (2397)
Resumes & cover letters (353)
Rett syndrome (27)
RNA editing (19)
RSV (79)
Schizophrenia (148)
Series A (248)
Series B (192)
Service/supplier (13)
Sickle cell disease (97)
Special edition (22)
Spinal muscular atrophy (157)
Sponsored (42)
Startups (3671)
State (2)
Stomach cancer (17)
Supply chain (105)
Tariffs (85)
The Weekly (57)
Vaccines (1018)
Venture capital (91)
Weight loss (384)
Women's health (92)
Worklife (18)
Date
Today (160)
Last 7 days (584)
Last 30 days (2261)
Last 365 days (30122)
2026 (3771)
2025 (30329)
2024 (35328)
2023 (40178)
2022 (51288)
2021 (55834)
2020 (54153)
2019 (46641)
2018 (35123)
2017 (32221)
2016 (31629)
2015 (37706)
2014 (31454)
2013 (26499)
2012 (28770)
2011 (29426)
2010 (27525)
Location
Africa (740)
Alabama (83)
Alaska (7)
Arizona (309)
Arkansas (13)
Asia (39452)
Australia (6461)
California (11405)
Canada (3306)
China (1105)
Colorado (481)
Connecticut (480)
Delaware (339)
Europe (85110)
Florida (1704)
Georgia (358)
Hawaii (3)
Idaho (62)
Illinois (868)
India (68)
Indiana (526)
Iowa (22)
Japan (433)
Kansas (128)
Kentucky (39)
Louisiana (26)
Maine (72)
Maryland (1389)
Massachusetts (8145)
Michigan (326)
Minnesota (632)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (122)
New Hampshire (79)
New Jersey (3018)
New Mexico (28)
New York (2992)
North Carolina (1462)
North Dakota (8)
Northern California (5575)
Ohio (336)
Oklahoma (21)
Oregon (42)
Pennsylvania (2292)
Puerto Rico (24)
Rhode Island (48)
South America (1111)
South Carolina (66)
South Dakota (1)
Southern California (4440)
Tennessee (177)
Texas (1761)
United States (40343)
Utah (337)
Vermont (1)
Virginia (266)
Washington D.C. (82)
Washington State (928)
West Virginia (4)
Wisconsin (110)
Wyoming (2)
725,055 Results for "ensysce biosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ensysce Biosciences Reports Third Quarter 2025 Financial Results
November 17, 2025
·
11 min read
Press Releases
Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain
January 29, 2026
·
4 min read
Press Releases
Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach
November 21, 2025
·
4 min read
Press Releases
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
January 8, 2026
·
5 min read
Press Releases
Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
December 3, 2025
·
4 min read
Press Releases
Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025
October 10, 2025
·
4 min read
Press Releases
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
December 10, 2025
·
4 min read
Press Releases
Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
November 18, 2025
·
4 min read
Press Releases
Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium
September 5, 2025
·
4 min read
Press Releases
Ensysce Biosciences’ Geoff Birkett to Chair the Fierce New Product Planning Summit 2025
August 20, 2025
·
4 min read
1 of 72,506
Next
